GR-1802
- Generic Name
- GR-1802
A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps
Phase 3
Not yet recruiting
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 228
- Registration Number
- NCT06516302
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath